Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Parkinson's Disease
Interventions: Trans-Resveratrol; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Parkinson's Disease, Mild Cognitive Impairment
Interventions: Exelon Patch (rivastigmine transdermal system), Placebo Patches; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastroenteritis Escherichia Coli, Immunisation
Interventions: Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: TCH346; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Volunteers
Interventions: AMG 378, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lake Forest, California • Overland Park, Kansas

Conditions: Crohn's Disease
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 39
States / cities: Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more

Conditions: Coronavirus Disease 2019
Interventions: Placebo, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more

Conditions: Pigmentation, Oxidative Stress
Interventions: Sunscreen application #1, Sunscreen application #2; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103), Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more

Conditions: Alzheimer Disease Related Dementia
Interventions: Probiotic Fermented Milk (PFM) Drink, Placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Intermittent Porphyria
Interventions: recombinant human porphobilinogen deaminase (Porphozym); Drug
Lead sponsor: Zymenex A/S; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Erectile Dysfunction
Interventions: Autologous Platelet Rich Plasma, Saline solution; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV
Interventions: Siempre Seguiré; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older · Male only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Memory Disorders
Interventions: Celecoxib; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: PL-3994; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cranbury, New Jersey

Conditions: Healthy Volunteers
Interventions: Control Diet, Base Diet with Broccoli; Other
Lead sponsor: USDA Beltsville Human Nutrition Research Center; Federal
Eligibility: 21 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Contact Lens Complication
Interventions: Acuvue® Oasys® Lenses (senofilcon A), 30-Day Bausch + Lomb PureVision (balafilcon A), Clariti® 1-Day (Somofilcon A); Device
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Depression During Pregnancy
Interventions: Virtual reality behavioral activation; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Kidney Stone
Interventions: Low Oxalate Diet before Weight Loss, Oral load of oxalate and sucralose before Weight Loss, Optifast VLCD Program, Optifast VLCD Transition Phase, Low Oxalate Diet after Weight Loss, Oral load of oxalate and sucralose after Weight Loss; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acid Reflux Disease, Obstructive Sleep Apnea
Interventions: Pantoprazole; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alzheimer's Disease
Interventions: ABT-126, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Fresno, California • Long Beach, California • San Francisco, California + 8 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 36
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more

Conditions: Healthy Elderly
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: South Miami, Florida

Search by objective public record fields.

RESvEraTrol in Parkinson's Disease (RESET)

Mild Cognitive Impairment in Parkinson's Disease

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

A Study to Evaluate the Ability of Sunscreen Products to Modulate the Effects of Deep UVA +/- HEV Blue Light Induced Pigmentation and Biomarkers of Cutaneous Oxidative Stress

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Probiotic Milk Drink for Gut and Brain Health in Older Adults and Caregivers

Porphozym in the Treatment of Acute Attacks in AIP

Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.

A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM

Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Daily Consumption of Well-Cooked Broccoli May Affect Glucosinolate Metabolites and Inflammatory Biomarkers

A Clinical Study Comparing the Comfort of Three Commercially Available Contact Lenses

Virtual Reality-enhanced Psychotherapy for Perinatal Depression

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649